Year: 2010
Type: editorial
Abstract: T he thiazolidinediones (TZDs) were introduced to the US market in 1997 as therapies to control hyperglycemia in patients with diabetes mellitus.This class of drugs (agonists of peroxisome proliferator-activated receptor ␥) has a wide range of biochemical effects, including lowering blood sugar by increasing insulin sensitivity.The TZDs were adopted relatively rapidly and achieved sales of nearly $3 billion in the United States in 2009.
Author: Frederick A. Masoudi
Institutions: Denver Health Medical Center, University of Colorado Denver
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2083780750